TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05120596: An Open-label, Phase I/II Study of T3P-Y058-739, a Genetically-modified Strain of the Bacterium Yersinia Enterocolitica, in Patients With Advanced Solid Tumours

Sponsor: T3 Pharmaceuticals AG · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,246,700

Rescue Site Savings

+$5,458,530

Unlock Full NCT05120596 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05120596 Rescue Dossier →